Quantitative in vivo and ex vivo confocal microscopy analysis of corneal cystine crystals in the Ctns−/− knockout mouse

Jennifer Simpson,1 Chyong Jy Nien,1 Kevin Flynn,1 Brian Jester,1 Stephanie Cherqui,2 James Jester1

1Gavin Herbert Eye Institute, University of California, Irvine CA; 2Scripps Research Institute, La Jolla CA

Purpose: The purpose of this study was to assess the ability of quantitative in vivo confocal microscopy to characterize the natural history and detect changes in crystal volume in corneas from a novel animal model of cystinosis, the cystinosin (Ctns−/−) mouse.

Methods: Two Ctns−/− mice and one C57Bl/6 mouse were examined at each of the following time points: 2, 3, 5, 7, 10, 12, and 14 months of age. In vivo confocal microscopy scans were performed in 4 different regions of the cornea per eye. After, animals were sacrificed and cornea blocks evaluated for cell morphology using phalloidin and lymphocytic infiltration using CD45 antibodies by ex vivo confocal microscopy. Cystine crystal content in the cornea was measured by calculating the pixel intensity of the crystals divided by the stromal volume using Metamorph Image Processing Software.

Results: Corneal crystals were identified in Ctns−/− eyes beginning at 3 months of age and increased in density until 7–12 months, at which time animals begin to succumb to the disease and corneas become scarred and neovascularized. Older Ctns−/− mice (7 months and older) showed the presence of cell infiltrates that stained positively for CD45 associated with progressive keratocyte disruption. Finally, at 12 months of age, decreased cell density and endothelial distortion were detected.

Conclusions: Confocal microscopy identified corneal crystals starting at 3 month old Ctns−/− eyes. Cystine crystals induce inflammatory and immune response with aging associated with loss of keratocyte and endothelial cells. These findings suggest that the Ctns−/− mouse can be used as a model for developing and evaluating potential alternative therapies for corneal cystinosis.

Cystinosis is an autosomal recessive lysosomal storage disease that is characterized by the accumulation of cystine crystals in various tissues, including the kidney, brain and eye [1-4]. The disease has been linked to mutations in the cystinosin (CTNS) gene (17p13) that codes for cystinosin, a trans-membrane protein responsible for the transport of the disulfide cystine amino acid out of the lysosome [5-9]. Different CTNS mutations are associated with a spectrum of clinical disease, with patients categorized into one of three severity groups based on their age at onset and symptoms [10]. The infantile onset of the most severe form of the disease, nephropathic cystinosis, results from the complete lack of cystine transport, with onset of renal failure by age 10 [11, 12]. Corneal cystine crystals appear within the first 16 months of life, increasing linearly during the first decade, until they plateau in early adolescence [13-16]. The non-nephropathic forms of cystinosis (juvenile and ocular cystinosis) demonstrate some residual membrane transport function and are associated with later onset and more limited systemic manifestations. However, corneal crystals are also present in these less severe forms of the disease [17].

Oral administration of cysteamine (HS-CH2-CH2-NH3) or β-mercaptopethalmine has been the mainstay of cystinosis therapy since 1994, when CYSTAGON® (cysteamine bitartrate, Mylan Pharmaceuticals Inc., Canonsburg, PA) was approved by the USA FDA. A free thiol, cysteamine reacts with cystine to produce the single sulfide amino acid cysteine, plus a cysteine-cysteamine mixed disulfide that exits the lysosome via the lysine transporter. By circumventing the transporter defect, oral cysteamine has significantly improved overall prognosis [12,18-20]. However, no improvements in ocular manifestations of the disease have been demonstrated with systemic treatment, presumably due to the lack of bioavailability of the drug in the cornea [11,21-23].

Cysteamine can be applied directly to the cornea via eye drops and is effective in reducing corneal crystals. However, the hourly dosing regimen that this medication requires is impractical for effective compliance [24]. Progressive photophobia, recurrent corneal erosions, foreign body sensation and visual deterioration associated with increasing concentrations of corneal crystals have therefore become a major long-term burden for patients having all forms of cystinosis [14,25,26].

The low levels of intracorneal cysteamine achieved via topical application are thought to result from poor compliance, limited corneal penetration and drug instability [15,21,22, 27-31]. Development of alternative treatments for corneal
disease has been hampered by the need for costly and time consuming human clinical trials in this low prevalence disease [20,32,33]. Further, the lack of an objective, quantitative methodology to assess corneal treatment efficacy has forced studies to rely on subjective patient complaints and semi-quantitative slit-lamp biomicroscopy grading.

Recently, a cystinosis (Ctns−/−) knockout mouse has been shown to develop cystine crystals in multiple tissues, including the cornea [34,35]. The ocular findings in the Ctns−/− mouse have been further characterized using slit lamp photography, assays of cystine levels in various ocular tissues, and standard histology. Cystine crystals were identified in the cornea as early as three months of age, while ocular tissue levels increased dramatically up to approximately 9–13 months. Most animals died between 13 and 20 months, with corneal vascularization identified histologically in older animals. Importantly, corneal cystine crystals were located within keratocytes throughout the stroma, but not in the epithelium, Bowman’s membrane, Descemet’s membrane or endothelium at any age [36].

The corneal findings in this murine knockout model appear to mimic disease progression in humans, where rapid linear increases in corneal crystals have been noted between birth and 6 years of age, with a plateau reached in the mid teenage years. Subsequent in vivo confocal microscopy studies in human nephropathic cystinosis patients 8–20 years old have demonstrated needle shaped hyperreflective bodies in the corneal epithelium and stroma of all patients [37-41].

In this study, we evaluated a quantitative method of confocal microscopy to characterize the natural history and localization of corneal crystal accumulation in the Ctns−/− mouse model. This further development of the Ctns−/− mouse model may enable more rapid and cost-effective screening of potential alternative therapies for corneal cystinosis.

METHODS

Mice: A total of seven C57Bl/6 (normal control) mice and 14 Ctns−/− knockout mice were used in this study. Two Ctns−/− mice and one C57Bl/6 mouse were examined at each of the following periods: 2, 3, 5, 7, 10, 12 and 14 months of age. This timeframe was developed from initial studies that showed most animals surviving to about 12 months, by which time severe ocular changes, including phthisis bulbi began to be noted.

At each time point, the selected animals were anesthetized with intraperitoneal injections of ketamine HCl (100 mg/Kg bodyweight; Bioniche Pharma, Lake Forest, IL) and xylazine (20 mg/Kg bodyweight; Lloyd Laboratories, Shenandoah, IO). Clinical abnormalities were then detected using slit lamp biomicroscopy and in vivo confocal microscopy (CM) to assess the presence and location of cystine crystals. Animals were then sacrificed by cervical dislocation under anesthesia, after which ex vivo evaluations were performed. All procedures were approved by the UCI IACUC and conducted in accordance with ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Slit lamp photography: Selected eyes were photographed using a Nikon D200 digital camera (Nikon Corporation, Tokyo, Japan) attached to a Nikon NS-1 slit lamp biomicroscope (Nikon Corporation), to identify the presence of crystals or abnormalities in the cornea.

In vivo confocal microscopy: Animals underwent in vivo CM scanning using a tandem scanning confocal microscope (TSCM; Tandem Scanning Corporation, Reston, VA) with a 24× surface-contact objective (numerical aperture, 0.6; working distance, 1.5 mm), encoder mike controller (Oriel 18011; Oriel, Stratford, CT) for focal plane control, and a camera (MTI VE-1000; Dage MTI, Michigan City, IN). One drop of preservative-free, Refresh Tears (Allergan, Irvine, CA) was placed on the tip of the objective as a coupling gel. All camera settings were kept constant throughout the experiment. For each eye, repeated data sets were obtained from select central and peripheral cornea locations. Three to five through-focus data sets were collected around these regions for assessment of cystine crystal volume using Metamorph Image Analysis software (Molecular Devices, Downingtown, PA).

Ex vivo confocal microscopy: The eyes of sacrificed animals were enucleated and placed in 2% paraformaldehyde, phosphate buffered saline, pH 7.4, for 10 min, after which corneas were removed and fixed overnight. Tissue blocks (2×2 mm) were then obtained and stained en bloc overnight at 4 °C with nucleic acid stain (DAPI; Molecular Probes, Eugene, OR) to identify nuclei, phalloidin (Alexa Fluor Rhodamine phalloidin; Invitrogen, Carlsbad, CA) to identify cell cytoskeleton and CD45 anti-mouse FITC conjugated antibody (Abcam, Cambridge, MA) to identify inflammatory cell infiltration.

Samples were placed on a microscope (Axiovert 200; Zeiss, Jena, Germany) and imaged with a laser confocal microscope system (LSM 510 META; Zeiss) equipped with a mode-locked titanium/sapphire laser (Chameleon; Coherent, Santa Clara, CA). The fluorescent signal detection from CD45, rhodamine phalloidin, and nucleic acid stain (DAPI) was obtained using the 488-nm, 543-nm and 740-nm laser lines of the argon, and helium-neon, and infrared/ femtosecond lasers.

Quantitative assessment of cystine crystal content: To measure the cystine crystal content in the cornea, through focus image data sets were analyzed by Metamorph Image Processing Software (Molecular Devices, Downingtown, PA). Initially, the stromal regions were extracted from the through focus data set and then thresholded using the Threshold subroutine to include all high intensity pixels representing light scattering from the cystine crystals. Threshold regions were set to include pixels intensity from 100 to 255. Pixels
within the threshold region were then counted using the “Measure” subroutine for all planes in the image stack to record the crystal volume. To calculate a “Percent Crystal Volume Index,” the crystal volume was divided by the extracted stromal volume.

Statistical analysis: Each eye was considered independently and results are reported as the mean±standard deviation (SD). Differences between age groups were evaluated statistically using GraphPad Prism™ 3.0 (GraphPad Software Inc., San Diego, CA), considering one-way Anova and Newman-Keuls Multiple Comparison tests.

RESULTS

Slit lamp photography: Small hyper-reflective needle-shaped deposits were first detected by biomicroscopy in the corneas of Ctns\(^{-/-}\) mice at 5 month of age, with more abundant crystals at 7 months (Figure 1A). Three eyes of the 14 Ctns\(^{-/-}\) animals developed phthisis bulbi, with central corneal opacification, loss of the normal ocular architecture and decreased ocular size at ages 7, 12, and 14 months (Figure 1B).

In vivo confocal microscopy: Using in vivo CM, no corneal cystine crystals were noted in any of the C57Bl/6 control mice at any time point. In the Ctns\(^{-/-}\) mice, cystine crystals (identified as small, highly reflective needle shaped deposits) were first detected in the cornea at 3 months of age, located both centrally and peripherally in the posterior cornea near the endothelium (Figure 2A). By seven months of age, Ctns\(^{-/-}\) mice developed more abundant and larger needle shaped crystals in the mid posterior stroma, again noted in both the central and peripheral cornea (Figure 2B). At 10 month of age, crystals appeared thicker, shorter and were also noted in the anterior stroma (Figure 2C). By 12 month of age, deposits appeared more punctate with markedly fewer needle shaped crystals (Figure 2D). Overall, these morphological changes suggest that crystals increase in quantity until 7 month of age, after which they begin to form aggregates, without significant increase in crystal quantity.

Measurement of cystine crystal content: To quantify the progression of cystine crystal deposits in the cornea, we first segmented the crystal volume from the 3-D in vivo CM scan by thresholding the images to contain just the crystal volume. The data set was then volume rendered to show the 3-D distribution of crystals within the mouse cornea (Figure 3). 3-D renderings of the crystals were then used to calculate the crystal volume in each cornea, and the volume recorded as the percent of total stromal volume. Quantitation of crystal volume showed that at 2 months of age, no crystals were detected in any Ctns\(^{-/-}\) mice, however a small number of crystals were detected by 3 months of age. Crystal volume significantly increased 15-fold from 3 to 4 month of age and fourfold from 4 to 7 month of age (p<0.05) or 56 fold overall. From 7 to 10 month of age, there was a significant decrease in crystal volume to half that detected at 7 months. There was no significant change in crystal volume between 10 and 12 months of age (Figure 4).

Ex vivo confocal microscopy: To evaluate changes to the keratocyte population associated with the deposition of cystine crystals, we stained corneas for actin to identify cell borders and DAPI to detect nuclei. Keratocytes in both the C57Bl/6 and 2–3 month old Ctns\(^{-/-}\) mice showed typical dendritic morphology and cortical actin staining (Figure 5A). Actin stained corneas of 5 month old Ctns\(^{-/-}\) mice demonstrated a few small cells near the limbus that stained intensively with phalloidin, suggesting the presence of stromal inflammation (Figure 5B). More abundant infiltrating cells were seen in the corneal periphery of 10 month old Ctns\(^{-/-}\) mice, often associated with disrupted keratocytes (Figure 5C). Both these features were more severe in 12 month old mice, with regions of keratocyte dropout (Figure 5C, asterisk) and decreased cell density (Figure 5D). Additionally, older mice (12 months) showed marked changes in the corneal endothelium, including loss of cell uniformity (polymegathism), polygonality (polymorphism) and increased cell size with formation of multinucleated cells (Figure 6).

To identify the presence of inflammatory cells, we stained corneas with antibodies to CD45, a marker for bone marrow derived cells. Cells with intense actin staining in the stroma showed positive staining for CD45 at 7 months of age (Figure 7A). Cells were located mostly in the periphery near the limbus but in older Ctns\(^{-/-}\) mice (10 months) inflammatory infiltrates were more prominent (Figure 6B) and present in

Figure 1. Slit lamp photography of a 7 month old Ctns\(^{-/-}\) mouse. A: The right eye with observed crystals in the cornea (arrows). B: The left eye of the same mouse with end stage corneal disease.
both the peripheral and central cornea. Overall, these findings suggest that cystine crystal deposition leads to a chronic inflammatory response associated with loss of stromal keratocytes and endothelial cells.

**DISCUSSION**

Using in vivo and ex vivo confocal microscopy, we have characterized the clinical progression of corneal disease in the Ctns−/− mouse. Our results show that cystine crystals are first noted at 3 months in the posterior cornea, later appearing in the anterior cornea and progressively increasing in density up to 7 months of age. More importantly, the volume of crystals appears to increase in quantity from 3 months to 7 month of age, after which they begin to form aggregates, without significant increases in crystal quantity. Increasing crystal volume also appeared to be associated with loss of keratocyte density and stromal inflammation from 5 to 10 months of age. Finally, many of the eyes appear to become phthisical as early as 7, but more commonly from 12 and 14 months of age.

Overall, our findings are similar to those of Kalatzis et al. [36], who characterized ocular cystinosis in the Ctns−/− mouse by slit-lamp biomicroscopy, histology and measurement of tissue cystine levels. In this earlier report, corneal cystine crystals were first detected by slit-lamp biomicroscopy at 3 months of age, the same time that in vivo CM detects corneal crystals localized to the posterior cornea. Furthermore, quantitative measurement of tissue cystine levels showed a 62 fold increase in corneal cystine concentration from 3 months to 9 months of age. This was comparable to the 56 fold increase in corneal cystine crystal volume detected by in vivo CM in the current study. Taken together, these findings suggest that in vivo CM is as sensitive as the biochemical measurement of tissue cystine levels in characterizing the early progression of corneal cystinosis in the Ctns−/− mouse. Importantly, in vivo CM is a non-invasive imaging technique that does not require sacrificing animals or the removal and processing of corneal tissue and therefore has distinct advantages to assessing corneal cystinosis by histology or biochemistry. Therefore, we propose that in vivo CM may be an objective and quantitative approach to assessing the progression of corneal cystinosis. More importantly, in vivo CM can be performed sequentially in the same eye over time, and can therefore be used as a sensitive approach to evaluating the effects of conventional and novel therapeutic strategies to
inhibit or remove cystine crystals in the cornea. However, future studies are required to demonstrate this capability.

It should be noted that while the cystine levels were reported to remain stable after 9 months based on biochemical analyses in this earlier report, overall cystine crystal volume appeared to significantly decrease by in vivo CM. Since decreased crystal volume was associated with a morphologic change in crystal shape from needle-like to punctate, the apparent decrease may be due in part to differences in the strength of the reflected light signals from these two types of structures. Thus, aggregation of crystals to form punctate deposits may give a low signal, leading to a decrease in measured volume. Why crystals change in shape is not clear, however, the loss of keratocytes and the increased inflammatory cell infiltration suggests that as cells dies, crystals are broken up and perhaps phagocytosed by inflammatory cells. The fact that corneal tissue cystine levels as measured by Kalatzis et al. [36] remain stable after 9 months, also supports the possibility that as cells die released crystals dissolve into the extracellular matrix, or are phagocytosed and removed by wander cells.

Our observations of corneal crystal accumulation also support the appropriateness of the Ctns−/− mouse as a model for human cystinosis, where 50%–70% of patients share the

| Age  | 2mo    | 3mo    | 4mo    | 7mo    | 10mo   | 12mo   |
|------|--------|--------|--------|--------|--------|--------|
| Mean ± SD | 0.05 ± 0.09 | 0.74 ± 0.37 | 2.81 ± 0.84 | 1.32 ± 0.35 | 0.95 ± 0.47 |

* = p < 0.001
ns = p value not significant

Figure 3. 3-D distribution of crystals within the cornea of a 7month old Ctns−/− mouse. Crystal volume was segmented from the 3-D in vivo CM scan by thresholding the images to contain just the crystal volume.

Figure 4. Cystine crystal quantification measured as the percentage (%) of crystals per stromal volume in different age groups. We observed a progressive increase in the crystal content in 3, 4, and 7 month old corneas that declined in the 10th and 12th month of age corneas (mo=month old; p<0.001 in 2 month versus 7 month, 2 month versus 10 month, 2 month versus 12 month, 2 month versus 4 month, 3 month versus 7 month, 3 month versus 10 month, 3 month versus 12 month, 3 month versus 4 month, 4 month versus 7 month, 4 month versus 10 month, 12 month versus 7 month, 10 month versus 7 month).
same genetic defect [5-8]. Although Ctns−/− mice did not receive systemic treatment with oral cysteamine (as do humans), corneal disease has been shown not to be responsive to such systemic therapy. In cross-sectional human studies, corneal crystals developed between birth and 6 years of age, reaching a maximum by the mid teenage years [13,14,17,25,42]. This lack of corneal response to conventional therapy underscores the importance of evaluating novel strategies to treat corneal cystinosis and the potential of the Ctns−/− mouse model to identify efficacious therapies.

In human case studies, corneal crystal deposition has been reported to start in the periphery and proceed posteriorly and centripetally, with crystals seen in the entire corneal stroma by age twenty [43,44]. This is in contrast to our findings where corneal crystals were first noted in the posterior stroma, both centrally and peripherally but proceeded to the anterior cornea with time. Our in vivo confocal images did not detect any crystals in the corneal endothelium or epithelium, in contrast to human confocal microscopy reports of crystals being present in the epithelium but absent in the endothelium [40,41]. Additionally, our results showed changes in the corneal endothelium including cell loss and increased cell size with formation of multinucleated cells that has not been reported in any study in humans.

Thus, the Ctns−/− mouse model seems to generally track with reported findings in humans. Finally, the findings of inflammatory cell migration, corneal neovascularization, and band keratopathy have also been reported in patients with nephropathic cystinosis who are in their twenties and thirties, again mirroring observations in the animal model [16].

In conclusion, the application of non-invasive CM, with the ability to sequentially evaluate and quantify crystal deposition in the same cornea, opens several interesting paths for future investigation. These include further studies assessing the effects of cystine crystals on keratocyte function and cell death. Such studies may help to elucidate molecular and cellular mechanisms involved in other organ systems such as the kidney and bone. In addition, in vivo CM of the Ctns−/− mouse may be a sensitive and efficient screening tool for alternate therapies that until now have been hampered by the absence of an animal model. Such therapies might include novel drug delivery, gene transfer and stem cell transplantation, for instance, umbilical mesenchymal stem cell [45] and human corneal stromal stem cells [46] that had...
shown to be a promising treatment for congenital corneal diseases involving keratocyte dysfunction. Importantly, novel treatment strategies useful in the Ctns−/− mouse may have wider application for other corneal diseases including mucopolysaccharidoses, corneal dystrophy, and scarring.

ACKNOWLEDGMENTS
This research was supported in part by a grant from the Cystinosis Research Foundation.

REFERENCES
1. Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med 2002; 347:11-21. [PMID: 12110740]
2. Kleta R, Kaskel F, Dohil R, Goodyer P, Guay-Woodford LM, Harms E, Ingelfinger JR, Koch VH, Langman CB, Leonard MB, Mannon RB, Sarval M, Schneider JA, Skovby F, Sonies BC, Thoene JG, Trauner DA, Gahl WA. First NIH/Office of Rare Diseases Conference on Cystinosis: past, present, and future. Pediatr Nephrol 2005; 20:452-4. [PMID: 15747161]
3. Schneider JA, Katz B, Melles RB. Update on nephropathic cystinosis. Pediatr Nephrol 1990; 4:645-53. [PMID: 2088469]
4. Schneider JA, Schulman JD. Cystinosis: a review. Metabolism 1977; 26:817-39. [PMID: 325318]
5. Forestier L, Jean G, Attard M, Cherqui S, Lewis C, van't Hoff W, Broyer M, Town M, Antignac C. Molecular characterization of CTNS deletions in nephropathic cystinosis: development of a PCR-based detection assay. Am J Hum Genet 1999; 65:353-9. [PMID: 10417278]
6. Kalatzis V, Cherqui S, Antignac C, Gasnier B. Cystinosin, the protein defective in cystinosis, is a H(+) -driven lysosomal cystine transporter. EMBO J 2001; 20:5940-9. [PMID: 11689343]
7. Kalatzis V, Cherqui S, Jean G, Cordier B, Cochat P, Broyer M, Antignac C. Characterization of a putative founder mutation in Ctns.
that accounts for the high incidence of cystinosis in Brittany. J Am Soc Nephrol 2001; 12:2170-4. [PMID: 11562417]
8. Kalatzis V, Nevo N, Cherqui S, Gasnier B, Antignac C. Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin. Hum Mol Genet 2004; 13:1361-71. [PMID: 15128704]
9. Cherqui S, Kalatzis V, Trugnan G, Antignac C. The targeting of cystinosin to the lysosomal membrane requires a tyrosine-based signal and a novel sorting motif. J Biol Chem 2001; 276:13314-21. [PMID: 11150305]
10. Attard M, Jean G, Forestier L, Cherqui S, van't Hoff W, Broyer M, Antignac C, Town M. Severity of phenotype in cystinosis varies with mutations in the CTNS gene: predicted effect on the model of cystinosin. Hum Mol Genet 1999; 8:2507-14. [PMID: 10556299]
11. Cantani A, Giardini O, Ciarnella Cantani A. Nephropathic cystinosis: ineffectiveness of cysteamine therapy for ocular changes. Am J Ophthalmol 1983; 95:713-4. [PMID: 6846466]
12. Gahl WA, Reed GF, Thoue H, Schulman JD, Rizzo WB, Jonas AJ, Denman DW, Schleselman JJ, Corden BJ, Schneider JA. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 1987; 316:971-7. [PMID: 3550461]
13. Iwata F, Kaiser-Kupfer MI. Ocular manifestations of metabolic disorders. Curr Opin Ophthalmol 1994; 5:79-83. [PMID: 10150832]
14. Tsilou E, Zhou M, Gahl W, Sieving PC, Chan CC. Ophthamlic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature. Surv Ophthalmol 2007; 52:97-105. [PMID: 17212992]
15. Tsilou ET, Rubin BI, Reed G, Caruso RC, Iwata F, Balog J, Gahl WA, Kaiser-Kupfer MI. Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy. Ophthalmology 2006; 113:1002-9. [PMID: 16603246]
16. Tsilou ET, Rubin BI, Reed GF, Iwata F, Gahl W, Kaiser-Kupfer MI. Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis. Cornea 2002; 21:173-6. [PMID: 11862089]
17. Anikster Y, Lucero Y, Gahl WA, Huizing M, Antignac C, Schneider JA, Gahl WA. Ocular nonnephropathic cystinosin: clinical, biochemical, and molecular correlations. Pediatr Res 2000; 47:17-23. [PMID: 10625078]
18. Cantani A, Giardini O, D'Eufemia P. The treatment of cystinosis with cysteamine. Ann Pediatr (Paris) 1991; 38:440. [PMID: 1929112]
19. Markello TC, Bernardini IM, Gahl WA. Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 1993; 328:1157-62. [PMID: 8455682]
20. Tsilou ET, Thompson D, Lindblad AS, Reed GF, Rubin B, Gahl W, Thoue J, Del Monte M, Schneider JA, Granet DB, Kaiser-Kupfer MI. A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br J Ophthalmol 2003; 87:28-31. [PMID: 12488257]
21. Hsuan JD, Harding JJ, Bron AJ. The penetration of topical cysteamine into the human eye. J Ocul Pharmacol Ther 1996; 12:499-502. [PMID: 8951686]
22. Jones NP, Postlethwaite RJ, Noble JL. Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%. Br J Ophthalmol 1991; 75:311-2. [PMID: 2036352]
23. Kaiser-Kupfer MI, Fujiwara L, Kuwabara T, Jain S, Gahl WA. Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N Engl J Med 1987; 316:775-9. [PMID: 3821824]
24. Soliman NA, El-Baroudy R, Rizk A, Bazaar H, Younan A. Nephropathic cystinosis in children: An overlooked disease. Saudi J Kidney Dis Transpl 2009; 20:436-42. [PMID: 19414947]
25. Kocabora MS, Ozbilen KT, Altunsoy M, Ahishali B, Taskapili M. Clinicopathological features of ocular cystinosis. Clin Experiment Ophthalmol 2008; 36:778-81. [PMID: 019128385]
26. Servais A, Moriniere V, Grunfeld JP, Noel LH, Goujon JM, Chadeauf-Vekemans B, Antignac C. Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping. Clin J Am Soc Nephrol 2008; 3:27-35. [PMID: 18178779]
27. Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab 2000; 71:100-20. [PMID: 11001803]
28. Iwata F, Kuehl EM, Reed GF, McCain LM, Gahl WA, Kaiser-Kupfer MI. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis. Mol Genet Metab 1998; 64:237-42. [PMID: 9758713]
29. Jain S, Kuwabara T, Gahl WA, Kaiser-Kupfer MI. Range of toxicity of topical cysteamine in rabbit eyes. J Ocul Pharmacol 1988; 4:127-31. [PMID: 3171336]
30. Kaiser-Kupfer MI, Gazzo MA, Datiles MB, Caruso RC, Kuehl EM, Gahl WA. A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis. Arch Ophthalmol 1996; 108:689-93. [PMID: 2185723]
31. Truong T, Sagar SM, Millard WJ, Shaw JL. Cysteamine induces cataracts in newborn rats. Invest Ophthalmol Vis Sci 1987; 28:1710-3. [PMID: 3654144]
32. Hippert C, Dubois G, Morin C, Disson O, Ibanes S, Jacquet C, Schwendener R, Antignac C, Kremer EJ, Kalatzis V. Gene transfer may be preventive but not curative for a lysosomal transport disorder. Mol Ther 2008; 16:1372-81. [PMID: 18578013]
33. Syres K, Harrison F, Tadlock M, Jester JV, Simpson J, Roy S, Salomon DR, Cherqui S. Successful treatment of the murine model of cystinosis using bone marrow cell transplantation. Blood 2009; 114:2542-52. [PMID: 19506297]
34. Cherqui S, Kalatzis V, Forestier L, Poras I, Antignac C. Identification and characterisation of the murine homologue of the gene responsible for cystinosis, Ctns. BMC Genomics 2000; 1:2. [PMID: 11121245]
35. Cherqui S, Sevin C, Hamard G, Kalatzis V, Sich M, Pequignot MO, Gogat K, Abitbol M, Broyer M, Gubler MC, Antignac C. Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis. Mol Cell Biol 2002; 22:7622-32. [PMID: 12370309]
36. Kalatzis V, Serratrice N, Hippert C, Payet O, Arndt C, Cazevieille C, Maurice T, Hamel C, Malecaze F, Antignac C, Muller A, Kremer EJ. The ocular anomalies in a cystinosis animal model mimic disease pathogenesis. Pediatr Res 2007; 62:156-62. [PMID: 17597652]

37. Alsuhaibani AH, Khan AO, Wagoner MD. Confocal microscopy of the cornea in nephropathic cystinosis. Br J Ophthalmol 2005; 89:1530-1. [PMID: 16234468]

38. Fung AT, Fraser-Bell S, Ojaimi E, Sutton G. In vivo confocal microscopy and polarizing microscopy of the cornea in a patient with nephropathic cystinosis. Clin Experiment Ophthalmol 2007; 35:292-3. [PMID: 17430525]

39. Grupcheva CN, Ormonde SE, McGhee C. In vivo confocal microscopy of the cornea in nephropathic cystinosis. Arch Ophthalmol 2002; 120:1742-5. [PMID: 12470153]

40. Labbé A, Niaudet P, Loirat C, Charbit M, Guest G, Baudouin C. In vivo confocal microscopy and anterior segment optical coherence tomography analysis of the cornea in nephropathic cystinosis. Ophthalmology 2009; 116:870-6. [PMID: 19410944]

41. Tavares R, Coelho D, Macario MC, Torres A, Quadrado MJ, Murta J. Evaluation of treatment with cysteamine eyedrops for cystinosis with confocal microscopy. Cornea 2009; 28:938-40. [PMID: 19654516]

42. Dufier JL, Dhermy P, Gubler MC, Gagnadoux MF, Broyer M. Ocular changes in long-term evolution of infantile cystinosis. Ophthalmic Paediatr Genet 1987; 8:131-7. [PMID: 3658340]

43. Dureau P, Broyer M, Dufier JL. Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine. J Pediatr Ophthalmol Strabismus 2003; 40:142-6. [PMID: 12795432]

44. Melles RB, Schneider JA, Rao NA, Katz B. Spatial and temporal sequence of corneal crystal deposition in nephropathic cystinosis. Am J Ophthalmol 1987; 104:598-604. [PMID: 3688102]

45. Liu H, Zhang J, Liu CY, Wang IJ, Sieber M, Chang J, Jester JV, Kao WW. Cell therapy of congenital corneal diseases with umbilical mesenchymal stem cells: lumican null mice. PLoS ONE 2010; 5:e10707. [PMID: 20502663]

46. Du Y, Carlson EC, Funderburgh ML, Birk DE, Pearlman E, Guo N, Kao WW, Funderburgh JL. Stem cell therapy restores transparency to defective murine corneas. Stem Cells 2009; 27:1635-42. [PMID: 19544455]